SP-0616: How will the new International Basic Safety Standards affect the medical physics practice?

A. Meghzifene, J. Le Heron
2013 Radiotherapy and Oncology  
This teaching lecture will focus on esophageal and gastric cancer. It remains a challenge to treat these patients outside a context of clinical trials. Different published delineation guidelines will be discussed and compared in esophageal and gastric cancer. The role of imaging modalities such as endoscopy, endoscopic ultrasound, CT scan, FDG-PET-CT in the delineation process and during (chemo) radiotherapy will be highlighted. Whether squamous cell carcinoma and adenocarcinoma of the
more » ... can be regarded as one tumor entity remains unclear. The same holds true for adenocarcinomas of the GE junction and the stomach. Organs at risk and dose constraints will be considered. The challenge of organ motion and tumor shrinkage during a course of (preoperative) chemoradiation will be discussed. Learning objectives: 1. To understand the impact on target definition and delineation when comparing preoperative versus postoperative chemoradiation 2. To understand the impact of different imaging modalities on the delineation process 3. To understand the impact of organ motion during treatment 4. To understand the impact of tumor shrinkage during treatment SP-0614 Clinical audit P. Scalliet 1 Early-stage esophageal cancer can be defined as locally resectable disease ((1) Ever since, several important developments (including Barrett surveillance, improvement of clinical staging by e.g. PET scanning, centralization of care, refined perioperative therapy, and more radical surgical techniques) have improved short-term and longterm outcome. However, 5-year survival after potentially curative surgical resection still rarely exceeds 35%. Many clinical trials have tested the potential value of neoadjuvant chemo-and/or radiotherapy to improve long-term outcome. In five randomized controlled trials (RCTs) the efficacy of neoadjuvant radiotherapy has been tested. A meta-analysis showed a nonsignificant 4% increase of 5 year survival rate.(2) Nine RCTs have been
doi:10.1016/s0167-8140(15)32922-4 fatcat:p3xgyssmdfh2xjm5yw2uzedhry